Evidence from observational uncontrolled trials and randomised studies in the last decade in OHSS high-risk patient populations suggests that the GnRH agonist for ovulation triggering significantly reduces, or even eliminates, the incidence of OHSS (71-75). Here, GNRH1 is linked to ovarian hyperstimulation syndrome.